Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers
Status:
Completed
Trial end date:
2017-11-22
Target enrollment:
Participant gender:
Summary
Treatment of angiomyolipomas is based on invasive techniques such as surgery or embolization.
Development of anti-angiogenic therapies is a major and growing field of research in
hypervascularized tumors. Angiomyolipomas have been shown to regress after prolonged
treatment with mTOR inhibitors (Sirolimus), but with a large proportion of secondary effects.
We showed recently that beta-blockers were able to induce regression of infantile hemagiomas.
Consequently, we looked for and found, histologically, in a few cases of angiomyolipomas the
presence of beta2 receptors.
The aim of the study is to estimate if beta-blockers could induce regression or stabilization
of renal angiomyolipomas in tuberous sclerosis in a pilot study.